All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Pain is a common symptom experienced by patients with multiple myeloma (MM), with opioids often prescribed as a pain management strategy. While opioids may be an integral part of pain management, opioid overuse has been associated with a significant public health crisis.1 The effect of chronic opioid use (COU) on outcomes in patients with MM has become an important area of investigation. The Multiple Myeloma Hub has previously held a symposium on pain management for patients with MM.
During the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIMBTR, Rodriguez presented results from a retrospective analysis on the prevalence and effect on outcomes of COU following autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with MM, which we are pleased to summarize below.1
This retrospective analysis aimed to describe the instances of COU, defined as a documented active prescription for 3 consecutive months, and the impact on long-term survival outcomes in 174 patients with MM aged ≥18 years old who underwent auto-HSCT from 2005 to 2019 at the University of Illinois Chicago, US. Overall survival (OS) and progression-free survival (PFS) were assessed at 6 months post-auto-HSCT. Daily opioid doses were converted to morphine milligram milliequivalents (MME). The median age in this study was 59 years (Table 1).
Table 1. Baseline patient characteristics*
Characteristics, % (unless otherwise specified) |
N = 174 |
---|---|
Median age (range), year |
59 (29–78) |
Gender |
|
Male |
51.7 |
Race |
|
White |
13.2 |
Black |
60.3 |
Hispanic |
13.8 |
Received novel agent-based induction |
83.3 |
Median time to auto-HSCT (range), months |
7 (1–144) |
Median number of prior lines of therapy(range), n |
1 (1–5) |
Received post-auto-HSCT maintenance |
71.0 |
IMWG-defined bone disease |
63.8 |
Paraprotein subtype |
|
IgG |
60.9 |
IgA |
19.0 |
Light chain |
20.1 |
High-risk FISH/karyotype |
|
Yes |
27.6 |
No or unknown |
72.4 |
ISS stage |
|
1 |
20.1 |
2 |
25.9 |
3 |
31.0 |
Auto-HSCT, autologous hematopoietic stem cell transplantation; FISH, fluorescence in situ hybridization; IgA, immunoglobulin A; IgG, immunoglobulin G; IMWG, International Myeloma Working Group; ISS, International Staging System. |
Table 2. COU rates and average MME per day*
Rates |
Patients with bone disease |
Patients without bone disease |
p value |
---|---|---|---|
COU rates, % |
52.4 |
54 |
0.98 |
Average MME/day, mg |
69.5 |
55.2 |
0.37 |
COU, chronic opioid use; MME, morphine milligram milliequivalents. |
Based on multivariable modified Poisson regression models, previous illicit drug use was associated with baseline opioid use, while the use of non-opioid analgesics, being retired, or being employed had a negative correlation (Table 3).
Table 3. Multivariable modified Poisson regression model of association with baseline opioid use*
Variable |
RR |
95% CI |
p value |
---|---|---|---|
Previous illicit drug use |
4.07 |
1.53–10.82 |
0.005 |
Use of non-opioid analgesics |
0.24 |
0.09–0.63 |
0.004 |
Retired |
0.49 |
0.29–0.83 |
0.008 |
Employed |
0.37 |
0.15–0.91 |
0.031 |
Bony lesions |
1.11 |
0.78–1.58 |
0.569 |
Fractures |
1.01 |
0.68–1.51 |
0.963 |
CI, confidence interval; RR, relative risk. |
In this retrospective analysis, high rates of baseline COU unrelated to bone disease were observed. High rates of opiate use at discharge including new users were noted, leading to COU at 6 months post-auto-HSCT in patients with MM. Patients who met the criteria for COU at 6 months post-auto-HSCT had inferior OS but not PFS, suggesting that opioid-related morbidity may impact patient outcomes.
While this study is limited by its single-center, retrospective nature, the results warrant further prospective investigation to improve the understanding of pain management in patients with MM. Alternative pain management strategies may prove beneficial in this patient population.
Disclaimer: All content produced by the Multiple Myeloma Hub is intended to adhere to the Centers for Disease Control and Prevention (CDC) Clinical Practice Guideline for Prescribing Opioids for Pain, issued in November 2022. Opioids are a class of highly addictive prescription painkillers; therefore, all information regarding their use must accurately describe the benefits and serious risks of misuse and abuse. The CDC recommendations do not apply to pain management related to sickle cell disease, cancer-related pain treatment, palliative care, or end-of-life care. Key principles to be taken into consideration include: i) nonopioid therapies are at least as effective as opioids for many common types of acute pain and are preferred for subacute and chronic pain; ii) before starting opioid therapy, clinicians should discuss with patients the realistic benefits and known risks; iii) when opioids are used, clinicians should prescribe immediate-release opioids at the lowest possible effective dosage; and iv) clinicians should regularly reevaluate with patients the benefits and risks of continued opioid therapy and when changing the dosage.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox